What red flag features differentiate pure red cell aplasia from myelodysplastic syndrome?

Red Flag Features Differentiating Pure Red Cell Aplasia from Myelodysplastic Syndrome

Pure red cell aplasia (PRCA) is distinguished from MDS by isolated erythroid lineage suppression with normal granulopoiesis and megakaryopoiesis, whereas MDS demonstrates dysplasia in ≥10% of cells in one or more lineages, specific cytogenetic abnormalities, or 5-19% blasts. 1

Key Diagnostic Red Flags

PRCA-Specific Features:

• Isolated erythroid suppression: Profound reticulocytopenia with severe reduction/absence of erythroid precursors beyond pronormoblast stage, but normal morphology of other lineages 2, 3
• No dysplasia: Absence of dyserythropoietic features (no ring sideroblasts, nuclear budding, bridging, or vacuoles) 4
• Normal cytogenetics: Typically lacks clonal chromosomal abnormalities 3
• T-cell abnormalities: Decreased absolute T lymphocyte subset numbers, often with T-cell clonality or STAT3 mutations 3, 5, 6
• Immune-mediated markers: Bone marrow immunohistochemistry shows C3, C4d, IgM, and IgG depositions that reduce after immunosuppression 3
• Secondary associations: Thymoma (23%), autoimmune diseases, large granular lymphocyte expansion 3, 7

MDS-Specific Features:

• Multilineage dysplasia: ≥10% dysplastic cells in ≥1 of 3 major bone marrow lineages (erythroid, granulocytic, megakaryocytic) 1
• Specific cytogenetic abnormalities: del(5q), del(20q), +8, -7/del(7q), or other MDS-associated karyotypes 1
• Blast elevation: 5-19% blasts in bone marrow 1
• Aberrant immunophenotype: Flow cytometry showing abnormal CD34 expression, atypical localization of immature progenitors 1
• Somatic mutations: Non-clonal hematopoiesis mutations (SF3B1, TET2, ASXL1, SRSF2, RUNX1) in 36-52% of cases 8, 9, 3
• Progressive marrow hypocellularity: Unlike PRCA, MDS can show hypocellularity but with persistent dysplasia 10, 4

Critical Diagnostic Algorithm

Step 1: Bone Marrow Morphology Assessment

• Count ≥500 cells on aspirate if possible 4
• Assess dysplasia severity: Moderate-to-severe dysplasia (binucleated forms, Howell-Jolly bodies, nuclear budding/bridging) excludes PRCA and indicates MDS 4
• Ring sideroblasts: >5 granules surrounding nuclear membrane or ≥1/3 circumference indicates MDS, not PRCA 4
• Erythroid precursor morphology: Normal morphology with simple absence favors PRCA; dysplastic features favor MDS 2, 4

Step 2: Lineage Involvement

• Single lineage (erythroid only): Consider PRCA, especially if other lineages morphologically normal 2, 3
• Bilineage or trilineage dysplasia: Diagnostic of MDS 1, 11, 12

Step 3: Cytogenetic Analysis

• Normal karyotype: More consistent with PRCA 3, 11
• MDS-associated abnormalities: Diagnostic of MDS even with minimal dysplasia 1

Step 4: Immunophenotyping and Molecular Studies

• T-lymphocyte subset quantification: Decreased absolute numbers suggest PRCA 5, 6
• Flow cytometry for aberrant markers: Abnormal CD34 expression, ALIP (abnormal localization of immature precursors) indicates MDS 1, 4
• Next-generation sequencing: Clonal hematopoiesis mutations alone may occur in PRCA; multiple non-clonal hematopoiesis mutations favor MDS 3

Step 5: Bone Marrow Biopsy Histology

• ALIP presence: ≥2 clusters of ≥3 blasts indicates MDS or AML, not PRCA 4
• Immunohistochemistry: C3, C4d, IgM, IgG depositions favor PRCA 3
• CD34 immunostaining: Excess CD34+ cells favor MDS 10, 4

Common Diagnostic Pitfalls

The most critical pitfall is misdiagnosing MDS with erythroid hypoplasia/aplasia as PRCA. 11, 12 This occurs when:

• Focusing only on erythroid hypoplasia without carefully assessing dysplasia in other lineages
• Missing subtle but significant dysgranulopoiesis or dysmegakaryopoiesis 12
• Failing to perform adequate cytogenetic analysis (minimum 20 metaphases if normal karyotype) 9
• Not obtaining adequate bone marrow biopsy (1-2 cm core preferred) 4

MDS with erythroid hypoplasia carries unfavorable prognosis with high blastic transformation rates, often preceded by myeloproliferative phase 11. These patients require MDS-directed therapy, not immunosuppression.

Treatment Response as Diagnostic Clue

• Response to cyclosporine A or mTOR inhibitors: 61-71% response rates strongly support PRCA diagnosis 3, 6
• Monitoring T-lymphocyte subsets during treatment: Rising absolute numbers with hemoglobin improvement confirms PRCA 5
• Failure of immunosuppression: Should prompt re-evaluation for MDS, particularly if dysplasia emerges or cytogenetic abnormalities develop 5

Persistent cytopenias for 4-6 months are required for MDS diagnosis 1, whereas PRCA typically presents more acutely with severe transfusion-dependent anemia.